NasdaqGM:PRCTMedical Equipment
PROCEPT BioRobotics (PRCT): Earnings Growth Forecasts Challenge Long-Standing Concerns Over Ongoing Losses
PROCEPT BioRobotics (PRCT) remains unprofitable, with net losses having grown at an annualized rate of 14.1% per year over the last five years and a negative profit margin. However, analysts are looking ahead, forecasting earnings growth of 71.13% per year and revenue increases of 18.8% annually. Both figures are well above the broader US market’s 10.5% projected growth. With profitability anticipated within the next three years, investors are weighing the promise of future gains against past...